- Home
- HCC vs HCM Comparison
HCC vs HCM Comparison
Compare HCC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- HCM
- Stock Information
- Founded
- HCC 2015
- HCM 2000
- Country
- HCC United States
- HCM Hong Kong
- Employees
- HCC N/A
- HCM N/A
- Industry
- HCC Coal Mining
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- HCM Health Care
- Exchange
- HCC Nasdaq
- HCM Nasdaq
- Market Cap
- HCC 3.0B
- HCM 2.6B
- IPO Year
- HCC 2017
- HCM N/A
- Fundamental
- Price
- HCC $63.52
- HCM $17.51
- Analyst Decision
- HCC Buy
- HCM
- Analyst Count
- HCC 6
- HCM 0
- Target Price
- HCC $68.80
- HCM N/A
- AVG Volume (30 Days)
- HCC 714.4K
- HCM 57.4K
- Earning Date
- HCC 10-29-2025
- HCM 08-07-2025
- Dividend Yield
- HCC 0.51%
- HCM N/A
- EPS Growth
- HCC N/A
- HCM N/A
- EPS
- HCC 0.77
- HCM 0.53
- Revenue
- HCC $1,221,350,000.00
- HCM $602,197,000.00
- Revenue This Year
- HCC N/A
- HCM $2.73
- Revenue Next Year
- HCC $41.76
- HCM $17.33
- P/E Ratio
- HCC $80.85
- HCM $6.26
- Revenue Growth
- HCC N/A
- HCM N/A
- 52 Week Low
- HCC $38.00
- HCM $11.51
- 52 Week High
- HCC $75.15
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- HCC 55.27
- HCM 61.26
- Support Level
- HCC $57.95
- HCM $17.19
- Resistance Level
- HCC $59.91
- HCM $18.30
- Average True Range (ATR)
- HCC 1.89
- HCM 0.35
- MACD
- HCC -3.02
- HCM 0.28
- Stochastic Oscillator
- HCC 97.71
- HCM 79.50
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.